Development of Alternative Human Models of Radiation-Induced Injuries (Extracorporeal Systems) (U01 Clinical Trial Not Allowed)
ID: 356635Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Award Range

$0 - $350K

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Cooperative Agreement

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/356635

Additional Information

http://grants.nih.gov/grants/guide/rfa-files/RFA-AI-24-067.html
Timeline
    Description

    The National Institutes of Health (NIH) has announced a funding opportunity titled "Development of Alternative Human Models of Radiation-Induced Injuries (Extracorporeal Systems)" aimed at supporting research into acute and delayed radiation injuries. This initiative seeks to develop innovative extracorporeal systems that accurately replicate human responses to radiation, facilitating the exploration of injury mechanisms and the testing of medical countermeasures. The funding, structured as a U01 cooperative agreement, has a total budget of $4 million, with plans to award six to eight grants in FY 2026. Interested applicants should note that the submission deadline is February 7, 2025, and they can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    RFA-AI-24-067.html
    The Department of Health and Human Services, through the National Institutes of Health (NIH) and specifically the National Institute of Allergy and Infectious Diseases (NIAID), has announced a funding opportunity focused on the development of alternative human models for studying radiation-induced injuries. The primary goal is to enhance understanding and mitigation of acute and delayed radiation injuries through the creation of extracorporeal systems that accurately mimic human responses. Research is encouraged to explore mechanisms of injury and test medical countermeasures (MCMs) that could be pivotal in public health emergencies. The funding opportunity, titled "Development of Alternative Human Models of Radiation-Induced Injuries," is structured as a U01 cooperative agreement, with an available budget of $4 million targeted for six to eight awards in FY 2026. Eligible applicants include diverse higher education institutions, nonprofits, and local government entities, but clinical trials are not permitted under this funding opportunity. Key application dates include an opening date of January 6, 2025, with a submission deadline of February 7, 2025. NIH expects proposals to incorporate rigorous methodologies, detailed milestones, and preliminary data to support the research's feasibility and significance in addressing the gaps in knowledge related to radiation-induced injuries. The initiative reflects an ongoing commitment to advancing medical preparedness for radiation incidents.
    Similar Opportunities
    Precision Approaches in Radiation Synthetic Combinations (PAIRS, R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Precision Approaches in Radiation Synthetic Combinations (PAIRS, R01 Clinical Trial Optional)" aimed at advancing research in cancer treatment through innovative synthetic vulnerabilities linked to radiation therapy. This initiative seeks R01 research projects that explore actionable vulnerabilities in tumors that can be paired with radiation responses, with the goal of developing effective anticancer strategies and integrating them into precision medicine. Eligible applicants include a wide range of entities such as higher education institutions, nonprofits, and governmental organizations, with applications due by 5 PM local time on September 7, 2025. For further inquiries, interested parties can contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov, and additional details can be found at the provided link: http://grants.nih.gov/grants/guide/pa-files/PAR-22-198.html.
    Systematic Testing of Radionuclides in Preclinical Experiments (STRIPE) (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Systematic Testing of Radionuclides in Preclinical Experiments (STRIPE)" aimed at advancing cancer therapeutics through research projects that utilize radionuclide-based therapies. This initiative specifically seeks R01 research proposals that investigate the effects of various radiation types on normal tissues, tumor cells, and the tumor microenvironment, with a focus on novel targeting strategies and pharmacodynamic biomarkers. The STRIPE program is critical for enhancing the understanding of radiopharmaceuticals in cancer treatment, with applications limited to direct costs of $500,000 per year and a maximum project duration of five years. Interested applicants must adhere to NIH guidelines, with submission deadlines starting January 5, 2025, and can direct inquiries to grantsinfo@nih.gov for further information.
    Clinical Characterization of Cancer Therapy-induced Adverse Sequelae and Mechanism-based Interventional Strategies (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Cancer Institute (NCI), has announced a funding opportunity titled "Clinical Characterization of Cancer Therapy-induced Adverse Sequelae and Mechanism-based Interventional Strategies." This initiative aims to support innovative research projects that investigate the adverse effects of cancer therapies, particularly those that lead to chronic comorbidities or delayed sequelae, with a focus on understanding the underlying mechanisms and developing therapeutic strategies to mitigate these long-term issues. The funding is open to a diverse range of applicants, including educational institutions, non-profits, and foreign organizations, and requires a Plan for Enhancing Diverse Perspectives (PEDP) as part of the application. Applications must be submitted electronically by January 5, 2025, with awards contingent on available funding and merit assessed through NIH's peer-review process. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    Research Resource for Human Organs and Tissues (U42 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Research Resource for Human Organs and Tissues" through a cooperative agreement mechanism (U42), aimed at supporting a program that provides and facilitates the availability of human tissues and organs for biomedical research. The initiative seeks to enhance the procurement, preservation, and distribution of diverse biospecimens, both normal and diseased, to aid researchers in understanding various diseases and addressing public health priorities. Applicants must demonstrate a proven track record in managing a human tissue and organ research resource, with direct costs capped at $720,000 over a potential five-year project period. The application period opens on December 24, 2024, with a submission deadline of September 25, 2025. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov.
    Notice of Intent to Publish a Funding Opportunity Announcement for Single Source: NCI National Clinical Trials Network - Network Radiotherapy and Imaging Core Services Centers (U24 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to publish a funding opportunity announcement for a cooperative agreement aimed at establishing a Network Radiotherapy and Imaging Core Services Center under the NCI National Clinical Trials Network (NCTN). This center will provide essential scientific and technical expertise for quality control, assurance, and image data management in NCTN trials that involve radiotherapy and imaging modalities, as well as support for other NCI-supported clinical trial programs. The funding opportunity is significant for enhancing cancer treatment research and is expected to have a total program funding of $8.8 million, with a ceiling of $8.14 million for the award. Interested private institutions of higher education should prepare their applications, as the anticipated application due date is in late February 2025, with an estimated award date set for March 1, 2026.
    Precision Approaches in Radiation Synthetic Combinations (PAIRS, R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Precision Approaches in Radiation Synthetic Combinations" (PAIRS) to support R21 research projects focused on identifying actionable vulnerabilities in tumors that respond to radiation therapy. The objective is to develop innovative radiation-synthetic combination strategies that enhance anticancer treatments, with applications ranging from pre-clinical research to early clinical trials. This initiative underscores the significance of precision medicine in oncology and encourages collaborative efforts to address complex cancer challenges. Eligible applicants include various institutions and organizations, with a funding ceiling of $275,000 over two years, and applications are due by September 7, 2025. For more information, interested parties can contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov or visit the official announcement at http://grants.nih.gov/grants/guide/pa-files/PAR-22-199.html.
    Research Projects to Enhance Applicability of Mammalian Models for Translational Research (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Research Projects to Enhance Applicability of Mammalian Models for Translational Research (R01 Clinical Trial Not Allowed)," aimed at improving the utility of mammalian cancer models in translational research. This initiative seeks projects that enhance the accuracy and application of models, such as organoids and tumoroids, to better represent human biology and inform clinical practices, addressing current limitations and fostering innovation in cancer research methodologies. Eligible applicants include a diverse range of organizations, such as higher education institutions and community-based organizations, with a maximum funding amount of $499,000 per year for projects not exceeding five years. Interested parties should submit their applications through Grants.gov, with deadlines beginning January 5, 2025, and can direct inquiries to grantsinfo@nih.gov for further information.
    Systematic Testing of Radionuclides in Preclinical Experiments (STRIPE) (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Systematic Testing of Radionuclides in Preclinical Experiments" (STRIPE), aimed at supporting innovative preclinical research projects that investigate the effects of radionuclide-based therapeutics on normal tissues, tumor cells, and the tumor microenvironment. This initiative encourages proposals that explore new targets for radiopharmaceuticals, develop drug combination strategies, and enhance theranostic capabilities, with a budget cap of $275,000 over a two-year period. The STRIPE program is critical for advancing cancer treatment methodologies by facilitating the transition of promising preclinical findings into clinical applications. Interested applicants can submit proposals starting January 16, 2025, and should direct inquiries to NIH Grants Information at grantsinfo@nih.gov.
    Systematic Testing of Radionuclides in Preclinical Experiments (STRIPE) (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Systematic Testing of Radionuclides in Preclinical Experiments" (STRIPE) through the R21 Exploratory/Developmental Research Grant mechanism. This initiative aims to support preclinical research focused on the effects of radionuclide-based therapeutics on normal tissues, tumor cells, and their microenvironments, encouraging collaborative applications that explore innovative therapeutic strategies. The maximum budget for successful proposals is set at $275,000 in direct costs over a two-year period, with applications due by various dates until October 16, 2025. Interested applicants can find additional information and application guidelines at the NIH website or contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov for further inquiries.
    Systematic Testing of Radionuclides in Preclinical Experiments (STRIPE) (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Systematic Testing of Radionuclides in Preclinical Experiments (STRIPE)" aimed at advancing research in cancer therapeutics. This initiative invites R01 research project applications that utilize innovative cancer biology methods to investigate the effects of radionuclide-based therapies on normal tissues, tumor cells, and the tumor microenvironment. The STRIPE program is critical for fostering research that may lead to effective treatments for metastatic diseases, emphasizing collaboration among experts in the field while excluding applications focused solely on clinical trials or computational methods. Interested applicants can apply for grants with a budget ceiling of $500,000 per year for a maximum project period of five years, with the application deadline set for May 7, 2025. For further inquiries, applicants may contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov or visit the additional information link at http://grants.nih.gov/grants/guide/pa-files/PAR-22-139.html.